205 related articles for article (PubMed ID: 8635265)
1. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans.
Haynes WG; Ferro CJ; O'Kane KP; Somerville D; Lomax CC; Webb DJ
Circulation; 1996 May; 93(10):1860-70. PubMed ID: 8635265
[TBL] [Abstract][Full Text] [Related]
2. Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men.
Spratt JC; Goddard J; Patel N; Strachan FE; Rankin AJ; Webb DJ
Br J Pharmacol; 2001 Oct; 134(3):648-54. PubMed ID: 11588120
[TBL] [Abstract][Full Text] [Related]
3. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044.
Plumpton C; Ferro CJ; Haynes WG; Webb DJ; Davenport AP
Br J Pharmacol; 1996 Sep; 119(2):311-4. PubMed ID: 8886414
[TBL] [Abstract][Full Text] [Related]
4. The peptide endothelin receptor antagonist, TAK-044, produces sustained inhibition of endothelin-1 mediated arteriolar vasoconstriction.
Ferro CJ; Haynes WG; Johnston NR; Lomax CC; Newby DE; Webb DJ
Br J Clin Pharmacol; 1997 Oct; 44(4):377-83. PubMed ID: 9354313
[TBL] [Abstract][Full Text] [Related]
5. Contribution of endogenous generation of endothelin-1 to basal vascular tone.
Haynes WG; Webb DJ
Lancet; 1994 Sep; 344(8926):852-4. PubMed ID: 7916401
[TBL] [Abstract][Full Text] [Related]
6. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men.
Strachan FE; Spratt JC; Wilkinson IB; Johnston NR; Gray GA; Webb DJ
Hypertension; 1999 Jan; 33(1 Pt 2):581-5. PubMed ID: 9931169
[TBL] [Abstract][Full Text] [Related]
7. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade.
Verhaar MC; Strachan FE; Newby DE; Cruden NL; Koomans HA; Rabelink TJ; Webb DJ
Circulation; 1998 Mar; 97(8):752-6. PubMed ID: 9498538
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo.
Ferro CJ; Spratt JC; Haynes WG; Webb DJ
Circulation; 1998 Jun; 97(23):2323-30. PubMed ID: 9639376
[TBL] [Abstract][Full Text] [Related]
9. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo.
Haynes WG; Strachan FE; Webb DJ
Circulation; 1995 Aug; 92(3):357-63. PubMed ID: 7634449
[TBL] [Abstract][Full Text] [Related]
10. Forearm vasoconstriction to endothelin-1 is mediated by ETA and ETB receptors in vivo in humans.
Haynes WG; Strachan FE; Gray GA; Webb DJ
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S40-3. PubMed ID: 8587426
[TBL] [Abstract][Full Text] [Related]
11. Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease.
Dhaun N; Ferro CJ; Davenport AP; Haynes WG; Goddard J; Webb DJ
Nephrol Dial Transplant; 2007 Nov; 22(11):3228-34. PubMed ID: 17556408
[TBL] [Abstract][Full Text] [Related]
12. Endogenous endothelin generation maintains vascular tone in humans.
Webb DJ
J Hum Hypertens; 1995 Jun; 9(6):459-63. PubMed ID: 7473528
[TBL] [Abstract][Full Text] [Related]
13. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension.
Taddei S; Virdis A; Ghiadoni L; Sudano I; Notari M; Salvetti A
Circulation; 1999 Oct; 100(16):1680-3. PubMed ID: 10525485
[TBL] [Abstract][Full Text] [Related]
14. Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis.
Helmy A; Jalan R; Newby DE; Johnston NR; Hayes PC; Webb DJ
Hepatology; 2001 Apr; 33(4):826-31. PubMed ID: 11283846
[TBL] [Abstract][Full Text] [Related]
15. Roles of endothelin receptors in the regional and systemic vascular responses to ET-1 in the anaesthetized ganglion-blocked rat: use of selective antagonists.
Allcock GH; Warner TD; Vane JR
Br J Pharmacol; 1995 Nov; 116(5):2482-6. PubMed ID: 8581288
[TBL] [Abstract][Full Text] [Related]
16. Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065.
Warner TD; Allcock GH; Vane JR
Br J Pharmacol; 1994 May; 112(1):207-13. PubMed ID: 8032643
[TBL] [Abstract][Full Text] [Related]
17. Local angiotensin-converting enzyme inhibition blunts endothelin-1-induced increase in forearm vascular resistance.
Abernethy DR; Laurie N; Andrawis NS
Clin Pharmacol Ther; 1995 Sep; 58(3):328-34. PubMed ID: 7554707
[TBL] [Abstract][Full Text] [Related]
18. ETA receptor-mediated responses to endothelin-1 and big endothelin-1 in the rat kidney.
Pollock DM; Opgenorth TJ
Br J Pharmacol; 1994 Mar; 111(3):729-32. PubMed ID: 8019752
[TBL] [Abstract][Full Text] [Related]
19. Evidence from receptor antagonists of an important role for ETB receptor-mediated vasoconstrictor effects of endothelin-1 in the rat kidney.
Wellings RP; Corder R; Warner TD; Cristol JP; Thiemermann C; Vane JR
Br J Pharmacol; 1994 Feb; 111(2):515-20. PubMed ID: 8004396
[TBL] [Abstract][Full Text] [Related]
20. Physiologic role of endothelin in maintenance of vascular tone in humans.
Haynes WG; Ferro CE; Webb DJ
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S183-5. PubMed ID: 8587357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
